Pulmonx (LUNG) Competitors

Pulmonx (NASDAQ:LUNG) and Paragon 28 (NYSE:FNA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, community ranking, risk and media sentiment.

Which has better earnings & valuation, LUNG or FNA?

Paragon 28 has higher revenue and earnings than Pulmonx. Paragon 28 is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$83.79M	4.22	-$60.84M	-$1.44	-6.22
Paragon 28	$216.39M	5.04	-$57.53M	-$0.74	-17.59

Does the media prefer LUNG or FNA?

In the previous week, Pulmonx had 9 more articles in the media than Paragon 28. MarketBeat recorded 10 mentions for Pulmonx and 1 mentions for Paragon 28. Pulmonx's average media sentiment score of 0.24 beat Paragon 28's score of 0.00 indicating that Pulmonx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Paragon 28	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer LUNG or FNA?

Pulmonx currently has a consensus price target of $12.75, indicating a potential upside of 42.30%. Paragon 28 has a consensus price target of $14.20, indicating a potential upside of 9.10%. Given Pulmonx's stronger consensus rating and higher probable upside, analysts plainly believe Pulmonx is more favorable than Paragon 28.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Paragon 28	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Do insiders & institutionals believe in LUNG or FNA?

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 63.6% of Paragon 28 shares are held by institutional investors. 5.7% of Pulmonx shares are held by insiders. Comparatively, 15.3% of Paragon 28 shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is LUNG or FNA more profitable?

Paragon 28 has a net margin of -25.31% compared to Pulmonx's net margin of -67.31%. Paragon 28's return on equity of -37.90% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-67.31%	-55.36%	-33.53%
Paragon 28	-25.31%	-37.90%	-18.22%

Does the MarketBeat Community believe in LUNG or FNA?

Paragon 28 received 2 more outperform votes than Pulmonx when rated by MarketBeat users. Likewise, 74.47% of users gave Paragon 28 an outperform vote while only 44.00% of users gave Pulmonx an outperform vote.

Company	Underperform	Outperform
Pulmonx	Outperform Votes 33 44.00%	Underperform Votes 42 56.00%
Paragon 28	Outperform Votes 35 74.47%	Underperform Votes 12 25.53%

Which has more volatility & risk, LUNG or FNA?

Pulmonx has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Paragon 28 has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500.

Summary

Paragon 28 beats Pulmonx on 11 of the 18 factors compared between the two stocks.